Prothena to Present New Preclinical Data for NEOD001 at 57th Annual American Society of Hematology Meeting

DUBLIN, Ireland, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that new preclinical data related to its NEOD001 program, health-related quality of life data in patients with AL amyloidosis, as well as follow-up case studies from patients in the NEOD001 Phase 1/2 multiple ascending dose trial, will be presented at the 57^th Annual American Society of Hematology (ASH) Meeting to be held December 5-8, 2015, in Orlando, FL, and during a Friday Satellite Symposia in advance of the meeting.

Friday Satellite Symposia:  Untangling Amyloidosis

In the Friday Satellite Symposia, titled "Untangling Amyloidosis," follow-up case studies from patients in the NEOD001 Phase 1/2 multiple ascending dose trial will be discussed in a presentation by Morie Gertz, M.D., of the Mayo Clinic.

• Date and Time:  Friday, December 4, 9:00 a.m. - 9:25 a.m. EST (full program runs 7:00 a.m. - 11:00 a.m. EST)
• Location:  Orange County Convention Center, West Building, Room W304EFGH

Poster Presentations

Preclinical data demonstrating the binding and clearance properties of NEOD001 and the related murine form of the antibody in various organs of patients with AL amyloidosis will be featured in the following poster presentation:

(Abstract #3016) NEOD001 Specifically Binds Aggregated Light Chain Infiltrates in Multiple Organs from Patients with AL Amyloidosis and Promotes Phagocytic Clearance of AL Aggregates In Vitro

• Presenter:  Wagner Zago, Prothena Biosciences Inc
• Session:  652/Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy
• Date and Time:  Sunday, December 6, 6:00 p.m. - 8:00 p.m. EST
• Location:  Orange County Convention Center, Hall A

Data contained in the published abstract was current as of August 4, 2015, and updated preclinical data will be presented at ASH.

In addition, a poster that highlights quality of life measures in patients with AL amyloidosis will also be presented:

(Abstract #4525) Health-Related Quality of Life in Patients With AL Amyloidosis: Qualitative Interviews With Physicians and Patients

• Presenter: Michelle White, Optum
• Session: 902/Health Services and Outcomes Research - Malignant Diseases: Poster III
• Date and Time: Monday, December 7, 6:00 p.m. - 8:00 p.m. EST
• Location:  Orange County Convention Center, Hall A

About NEOD001

NEOD001 is a humanized monoclonal antibody that specifically targets the circulating soluble amyloid and deposited insoluble amyloid that accumulates in both the AL and AA forms of amyloidosis. Patients with AL amyloidosis may be eligible to enroll in one of two clinical trials for NEOD001. The VITAL Amyloidosis Study, a double-blind, placebo-controlled, global Phase 3 registrational trial, is evaluating NEOD001 in newly-diagnosed, treatment-naïve patients with AL amyloidosis, and will assess a composite of all-cause mortality or cardiac hospitalizations in addition to biomarker, functional and quality of life endpoints. The PRONTO trial, a double-blind, placebo-controlled, global Phase 2b registration-directed trial, will evaluate NEOD001 in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction, and will assess NT-proBNP best response over 12 months in addition to other functional biomarker, and quality of life endpoints. More information on The VITAL Amyloidosis Study and the PRONTO trial is available or will be provided at www.clinicaltrials.gov.

About AL Amyloidosis

Systemic amyloidoses are a complex group of progressive diseases caused by tissue deposition of misfolded proteins that result in progressive organ damage. The most common type, AL amyloidosis or primary amyloidosis, involves a hematological disorder caused by plasma cells that produce misfolded immunoglobulin light chain resulting in deposits of abnormal AL protein (amyloid) in the tissues and organs of individuals with this disease. There are no approved treatments for AL amyloidosis, and none that directly target potentially toxic forms of the AL protein. AL amyloidosis is a rare disorder and it is estimated that about 30,000 to 45,000 patients in the U.S. and Europe suffer from this disease. Both the causes and origins of AL amyloidosis remain poorly understood. For more information on AL amyloidosis, please visit the websites of the Amyloidosis Support Group and the Amyloidosis Foundation.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. The Company is developing antibody-based product candidates that target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and psoriasis and other inflammatory diseases (PRX003). For more information, please visit the Company's web site at www.prothena.com.

Contacts:

Investors: Tran Nguyen, CFO
650-837-8535, IR@prothena.com

Media: Ellen Rose, Head of Communications 
650-922-2405, ellen.rose@prothena.com